Unity Biotechnology (NASDAQ:UBX – Get Rating) had its price target decreased by investment analysts at Wedbush from $35.00 to $5.00 in a report released on Tuesday, The Fly reports. Wedbush’s price target points to a potential upside of 156.41% from the company’s previous close. UBX has been the subject of a number of other reports. […]
Arshad M. Khanani MD, MA, FASRS Director of Clinical Research at Sierra Eye Associates Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO . | March 27, 2023